Literature DB >> 1847721

Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy.

H Holdaas1, A Hartmann, M G Lien, L Nilsen, J Jervell, P Fauchald, L Endresen, O Djøseland, K J Berg.   

Abstract

An open, randomized, cross-over study was undertaken to assess the effects of lisinopril and nifedipine on albumin excretion, renal haemodynamics and segmental tubular reabsorption in overt diabetic nephropathy. The study consisted of a 4-week run-in period, a 3-week active treatment period, a 4-week wash-out period and a second 3-week active treatment period. Twelve patients with type 1 diabetes with albuminuria, mild to moderate hypertension and a serum creatinine level of less than 200 mumol l-1 were included. Lisinopril reduced albumin excretion from 1343 +/- 337 micrograms min-1 to 879 +/- 299 micrograms min-1 (P less than 0.01), whereas nifedipine was without effect, 1436 +/- 336 micrograms min-1 vs. 1319 +/- 342 micrograms min-1. Glomerular filtration rate (GFR) was unchanged by either drug. Both drugs increased effective renal plasma flow (ERPF) by about 20%. No differences between the drugs were observed with regard to their effect on renal haemodynamic parameters. By contrast, nifedipine exerted an inhibitory effect on several proximal tubular transport markers, whereas lisinopril was without effect. The different actions on tubular transport mechanisms exerted by lisinopril and nifedipine may contribute to the observed effect on albumin excretion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847721     DOI: 10.1111/j.1365-2796.1991.tb00325.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  10 in total

Review 1.  Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.

Authors:  T Baba; S Neugebauer; T Watanabe
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 2.  Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus.

Authors:  K L Goa; M Haria; M I Wilde
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 3.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 4.  Non-steroidal anti-inflammatory drugs and angiotensin converting enzyme inhibitors: a commonly prescribed combination with variable effects on renal function.

Authors:  N D Sturrock; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

Review 5.  Renoprotective role of ACE inhibitors in diabetic nephropathy.

Authors:  C E Mogensen
Journal:  Br Heart J       Date:  1994-09

Review 6.  Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.

Authors:  H D Langtry; A Markham
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

Review 7.  Renal long-term effects of calcium antagonist treatment in patients with diabetes mellitus.

Authors:  E Jungmann; K H Usadel
Journal:  Clin Investig       Date:  1992-10

8.  Hypertension and non-insulin-dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist.

Authors:  G Crepaldi; A Carraro; E Brocco; L Adezati; D Andreani; G Bompiani; P Brunetti; D Fedele; R Giorgino; G Giustina
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

Review 9.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

Review 10.  Antihypertensive agents: a long way to safe drug prescribing in children.

Authors:  Nida Siddiqi; Ibrahim F Shatat
Journal:  Pediatr Nephrol       Date:  2019-11-01       Impact factor: 3.651

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.